American Association for Cancer Research
Browse
00085472can171805-sup-184940_2_supp_4398251_mzkbg1.pdf (77.93 kB)

Figure S3 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Download (77.93 kB)
journal contribution
posted on 2023-03-31, 01:29 authored by Jiajia Shen, Pengyu Li, Xuejing Shao, Yang Yang, Xiujun Liu, Min Feng, Qiang Yu, Ronggui Hu, Zhen Wang

Interaction of p53 with RING1 is independent of RNF2

Funding

National Natural Science Foundation of China

CAMS Innovation Fund for Medical Sciences

History

ARTICLE ABSTRACT

As a component of the transcriptional repression complex 1 (PRC1), the ring finger protein RING1 participates in the epigenetic regulation in cancer. However, the contributions of RING1 to cancer etiology or development are unknown. In this study, we report that RING1 is a critical negative regulator of p53 homeostasis in human hepatocellular and colorectal carcinomas. RING1 acts as an E3 ubiquitin (Ub) ligase to directly interact with and ubiquitinate p53, resulting in its proteasome-dependent degradation. The RING domain of RING1 was required for its E3 Ub ligase activity. RING1 depletion inhibited the proliferation and survival of the p53 wild-type cancer cells by inducing cell-cycle arrest, apoptosis, and senescence, with only modest effects on p53-deficient cells. Its growth inhibitory effect was partially rescued by p53 silencing, suggesting an important role for the RING1–p53 complex in human cancer. In clinical specimens of hepatocellular carcinoma, RING1 upregulation was evident in association with poor clinical outcomes. Collectively, our results elucidate a novel PRC1-independent function of RING1 and provide a mechanistic rationale for its candidacy as a new prognostic marker and/or therapeutic target in human cancer.Significance: These results elucidate a novel PRC1-independent function of RING1 and provide a mechanistic rationale for its candidacy as a new prognostic marker and/or therapeutic target in human cancer. Cancer Res; 78(2); 359–71. ©2017 AACR.